Image

U.S. Psychedelic Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Country Level
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Country Level
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

U.S. Psychedelic Drugs Market, By Source (Synthetic, Natural), Type (Empathogens, Dissociatives, Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End-User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2029.

Market Analysis and Size

In recent years, the psychedelic drugs market is anticipated to grow rapidly during the forecast period. People are becoming more aware of mental health issues around the world. Mental health illnesses affect 13% of the world's population, according to a research published by the World Health Organization (WHO) in 2021. As per the report, one out of every five years is spent disabled due to mental health issues. People have sought treatment because of their severe conditions. Furthermore, some groups have initiated public awareness campaigns to promote the use of psychedelic medicines to treat mental illnesses.

Data Bridge Market Research analyses that the psychedelic drugs market was valued at USD 2834.72 million in 2021 and is expected to reach USD 9818.68 million by 2029, registering a CAGR of 16.8% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Psychedelic drugs are used to enhance or change sensory perceptions, cognitive processes, energy levels and spiritual experiences. The three forms of psychedelic drugs are empathogens, dissociative drugs, and serotonergic drugs. These drugs are used to treat major depressive disorder, treatment-resistant depression, panic disorder, post-traumatic stress disorder, and opiate addiction, among other conditions.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Source (Synthetic, Natural), Type (Empathogens, Dissociatives, Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)

Market Players Covered

Avadel (Ireland), Celon Pharma S.A. (Poland), Johnson & Johnson Private Limited (US), Hikma Pharmaceuticals PLC (UK), Amneal Pharmaceuticals LLC. (US), NeuroRx, Inc. (US), Jazz Pharmaceuticals, Inc. (Ireland), COMPASS (UK), Develco Pharma Schweiz AG (Switzerland), Douglas Pharmaceuticals Limited (New Zealand)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Surge in drug approvals and new product launches
  • Rising investment for the development of advanced technologies

U.S. Psychedelic Drugs Market Dynamics

Drivers

  • Increasing prevalence of depression and mental disorders

Increased use of illicit substances has increased depression and mental problems. As a result of the rising prevalence of depression and mental diseases, demand for psychedelic substances is predicted to rise, propelling the industry forward.

  • Rising awareness towards mental health

Psychedelic substances have become more well-known due to advertisements, public awareness initiatives, and other means. People have been encouraged to choose the proper treatment for mental disorders processes and specialists due to the awareness campaigns, which has increased demand for psychedelic medications. As a result, increased mental health awareness is likely to be a key driver of market expansion.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of psychedelic drugs market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, the decentralization of pharmacies will expand the psychedelic drugs market. Additionally, high disposable income and increasing acceptance of psychedelic drugs for the treatment of depression will expand the psychedelic drugs market. Along with this, rising geriatric population and introduction of novel psychedelic drugs will enhance the growth rate of the market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the psychedelic drugs market growth. Along with this, surge in drug approvals and new product launches will further propel the 'market's growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the psychedelic drugs market growth during the forecast period.

Restraints/Challenges

On the other hand, the delay in the drug approval process and poor order communication between physicians and pharmacists will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the psychedelic drugs market. Additionally, strict regulatory policies and surging side effects of psychedelic drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This psychedelic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the psychedelic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Psychedelic drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on U.S. Psychedelic Drugs Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country, prompting the World Health Organization (WHO) to declare it a public health emergency.

The market is growing due to increased demand for psychedelic drugs during the COVID-19 outbreak. COVID-19 infection rates were expanding over the world. People all throughout the world faced great trauma and stress as a result of the sudden imposition of the lockdown by governments across the globe.

Recent Development

  • In January 2020, Janssen Pharmaceuticals, Inc,. submitted a Type II Varian Application for SPRAVATO nasal spray to the European Medicines Agency. The proposal requests that nasal spray be used more widely as an acute, short-term therapy for depression symptoms. This would assist the business in generating revenue.

U.S. Psychedelic Drugs Market Scope

The psychedelic drugs market is segmented on the basis source, type, drugs, application, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Source

  • Synthetic
  • Natural

Type

  • Empathogens
  • Dissociatives
  • Others

Drugs

  • Gamma-Hydroxybutyric Acid
  • Ketamine
  • Psilocybin
  • Others

Application

  • Narcolepsy
  • Treatment Resistant Depression
  • Major Depressive Disorder
  • Opiate Addiction
  • Post-Traumatic Stress Disorder
  • Others

Route of Administration

  • Oral
  • Inhalation
  • Injectable

End User

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Competitive Landscape and U.S. Psychedelic Drugs Market Share Analysis

The psychedelic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to psychedelic drugs market.

Some of the major players operating in the U.S. psychedelic drugs market are:

  • Avadel (Ireland)
  • Celon Pharma S.A. (Poland)
  • Johnson & Johnson Private Limited (US)
  • Hikma Pharmaceuticals PLC (UK)
  • Amneal Pharmaceuticals LLC. (US)
  • NeuroRx, Inc. (US)
  • Jazz Pharmaceuticals, Inc. (Ireland)
  • COMPASS (UK)
  • Develco Pharma Schweiz AG (Switzerland)
  • Douglas Pharmaceuticals Limited (New Zealand)   


SKU-
Why Choose Us


Frequently Asked Questions

The market value for U.S. Psychedelic Drugs Market is expected USD 9818.68 million by 2029.
The Psychedelic Drugs Market is to grow at a CAGR of 16.8% during the forecast by 2029 .
The expansion of the U.S. Psychedelic Drugs Market will be fueled by the rising need to minimize medication errors and increasing prevalence of chronic diseases. Additionally, increasing expenditure on healthcare infrastructure and increasing geriatric population will enhance the growth rate of U.S. psychedelic drugs market.
The major players operating in the U.S. Psychedelic Drugs Market are Avadel (Ireland), Celon Pharma S.A. (Poland), Johnson & Johnson Private Limited (US), Hikma Pharmaceuticals PLC (UK), Amneal Pharmaceuticals LLC. (US), NeuroRx, Inc. (US), Jazz Pharmaceuticals, Inc. (Ireland), COMPASS (UK), Develco Pharma Schweiz AG (Switzerland), Douglas Pharmaceuticals Limited (New Zealand).